Integrin/CD44-targeted liposomes remodel the pulmonary microenvironment to alleviate acute exacerbation of pulmonary fibrosis
Authors:
- Xinmei HuangXHXinmei Huang
- Yingwei ZhangYZYingwei Zhang
- Xin YanXYXin Yan
- Cheng JiangCJCheng Jiang
- Zimu WangZWZimu Wang
- Di SunDSDi Sun
- Yan LiYLYan Li
- Jingjing DingJDJingjing Ding
- Xiaohua QiuXQXiaohua Qiu
- Mengshu CaoMCMengshu Cao
- 20 November 2025
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114427
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82400089)
- Natural Science Foundation of Jiangsu Province (BK20230140)
This publication has 52 references indexed in Scilit:
- Development and characterization of pH-sensitive zerumbone-encapsulated liposomes for lung fibrosis via inhalation routeEuropean Journal of Pharmaceutics and Biopharmaceutics, 2024
- Construction of the pulmonary bio-adhesive delivery system of nintedanib nanocrystalline for effective treatment of pulmonary fibrosisInternational Journal of Pharmaceutics, 2024
- Hybrid biomineralized nanovesicles to enhance inflamed lung biodistribution and reduce side effect of glucocorticoid for ARDS therapyJournal of Controlled Release, 2024
- Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in MiceInflammation, 2023
- Magnetic liposome as a dual-targeting delivery system for idiopathic pulmonary fibrosis treatmentJournal of Colloid and Interface Science, 2023
- Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapyJournal of Controlled Release, 2022
- SimplifyEnrichment: A Bioconductor Package for Clustering and Visualizing Functional Enrichment ResultsGenomics, Proteomics & Bioinformatics, 2022
- Novel drug delivery systems and disease models for pulmonary fibrosisJournal of Controlled Release, 2022
- Nanotherapeutics in the treatment of acute respiratory distress syndromeLife Sciences, 2021
- Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosisRespirology Case Reports, 2017